Obefazimod

Obefazimod is an investigational new drug that is being evaluated for the treatment of ulcerative colitis.^[1] It is miR-124 micro RNA upregulator.^[2] Obefazimod was developed by the French biotech company Abivax SA, whose shares rose by more than 500% when the phase 3 data showed promising results.

Obefazimod

Identifiers
IUPAC name 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine
CAS Number	1258453-75-6
PubChem CID	49846599
DrugBank	DB14828
ChemSpider	34537418
UNII	26RU378B9V
KEGG	D12345
ChEMBL	ChEMBL4297344
Chemical and physical data
Formula	C16H10ClF3N2O
Molar mass	338.71 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=CC2=C(C(=C1)Cl)N=C(C=C2)NC3=CC=C(C=C3)OC(F)(F)F
InChI InChI=1S/C16H10ClF3N2O/c17-13-3-1-2-10-4-9-14(22-15(10)13)21-11-5-7-12(8-6-11)23-16(18,19)20/h1-9H,(H,21,22) Key:OZOGDCZJYVSUBR-UHFFFAOYSA-N